论文部分内容阅读
目的探讨瑞舒伐他汀治疗冠心病的安全性和近期疗效。方法 132例冠心病患者,采用简单抽样法随机分成瑞舒伐他汀组(A组)72例和阿托伐他汀组(B组)60例。对比两组患者用药后近期治疗效果及不良反应发生情况,记录其血脂各指标变化情况。结果 1治疗后A组总有效率87.5%,高于B组的68.3%差异具有统计学意义(P<0.05);2治疗后A组血清总胆固醇(TC)、三酰甘油(TG)及低密度脂蛋白胆固醇(LDL-C)等指标均较给药前明显下降,高密度脂蛋白胆固醇(HDL-C)则显著上升,指标变化幅度大于B组,对比差异具有统计学意义(P<0.05);3治疗后,两组均无严重不良反应发生,对比差异无统计学意义(P>0.05)。结论对冠心病患者给予瑞舒伐他汀方案,近期疗效显著,不良反应发生率低,安全可靠,值得临床推广。
Objective To investigate the safety and short-term efficacy of rosuvastatin in the treatment of coronary heart disease. Methods A total of 132 patients with coronary heart disease were randomly divided into two groups: 72 patients in the rosuvastatin group (A group) and 60 patients in the atorvastatin group (Group B). Compare the short-term treatment effect and adverse reaction of two groups of patients after treatment, and record the change of each index of blood lipid. Results After treatment, the total effective rate of group A was 87.5%, which was higher than that of group B (68.3%) (P <0.05). After treatment 2, the levels of total cholesterol (TC), triglyceride LDL-C and other indexes were significantly lower than those before treatment, while HDL-C increased significantly (P <0.05) ); 3 after treatment, no serious adverse reactions occurred in both groups, the difference was not statistically significant (P> 0.05). Conclusions The regimen of rosuvastatin in patients with coronary heart disease has obvious curative effect in the short term, low incidence of adverse reactions, safe and reliable, and worthy of clinical promotion.